asco 2018 - keynote 042 - keytruda as a single agent compared to doublet chemotherapy for nsclc
Published 5 years ago • 978 plays • Length 11:15Download video MP4
Download video MP3
Similar videos
-
11:29
asco 2018 keynote189 - cisplatin or carboplatin with alimta & keytruda - practice changing approach?
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
3:34
asco 2018 - keynote 158 - keytruda in previously treated, now relapsing patients with sclc
-
8:46
keytruda is now approved in combination with chemo for advanced non-squamous nsclc
-
12:26
asco 2018 - potential showdown of two positive trials? keynote 407 and impower 131
-
8:13
asco 2021 lung recap: fda analysis of immunotherapy with or without chemo in adv nsclc and low pdl-1
-
6:32
asco 2019 lung cancer round table - new cancer research: long term outcomes of pembrolizumab
-
4:35
immunotherapy combinations
-
4:42
asco lung cancer roundtable - new combinations chemo immunotherapy for extensive stage sclc
-
9:41
gracecast- asco lung 2020- enhertu and the potential for treatment of her2 positive nsclc
-
2:05
lung cancer video library - combinations of immunotherapy agents in advanced nsclc: current status
-
7:28
egfrm nsclc: should we treat with durvalumab? - asco lung review 2022
-
11:12
the future of cancer immunotherapy: combination treatments
-
7:15
unresectable nsclc - treatment standard concurrent chemo & rad followed by immunotherapy, approach f
-
15:53
gracecast-054_lung-cancer_socinski on advanced nsclc maintenance therapy q&a
-
5:39
gracecastuc 127 lung_molecular markers predicting the best chemotherapy to use in lung cancer
-
23:32
gracecast-077_lung-cancer_asco 2011 highlights - advanced/metastatic nsclc
-
2:26
what have we learned from the start trial of immunotherapy in locally advanced nsclc?